What does the FDA record actually say?
Start with the pharmacy rules. Then see what the older FDA records and the public meeting mean.
The US Food and Drug Administration (FDA) had given epitalon no approval at the 28 September 2026 check.
When a pharmacist or doctor prepares a medicine to order, that is called compounding.
On 26 September 2026, the reviewed rules did not allow a regular pharmacy to make epitalon from its raw ingredient for a patient.
How did the public record develop?
- 2010: epitalon gained orphan status, which supports work on medicines for rare diseases, for an inherited eye disease.
- 2016: epitalon’s orphan status for work on the rare eye disease ended. The record does not say why.
- FDA page updated 22 April 2026: the people or groups who asked FDA to allow epitalon as a raw ingredient had taken back their requests. FDA still listed its safety concerns about epitalon.
- July 2026 review: FDA staff recommended against adding epitalon to the permitted compounding ingredient list.
- 28 September 2026 check: FDA had published no written account of the July panel meeting or official record of its vote.
Orphan status is not approval. It did not lead to an approved epitalon medicine.
The page gives its update date, not the date the requests were taken back. Taking them back did not mean FDA had cleared epitalon for use.
Did taking back a request let pharmacies use epitalon?
No. Taking back a request does not meet the rules for ingredients a pharmacy may use to make medicine.
As of 28 September 2026, epitalon was not on the list of raw ingredients permitted for this use. It was also outside FDA’s temporary policy for some ingredients awaiting review.
Under that policy, FDA says it will hold off on action against pharmacies using certain listed ingredients if they meet its conditions. That is not legal approval, and epitalon is not covered.
The reviewed FDA documents found no official written standard for checking the quality of epitalon as a drug ingredient. They also found no approved drug containing it.
Those are other ways a raw ingredient can meet the pharmacy rules. Epitalon met none of them.
Did the panel meeting change the rule?
An advisory panel gives advice. Its meeting or vote does not itself change the law; the FDA has to complete a formal rule-making process.
The staff’s recommendation was made before the meeting. It was not a final agency decision.
Ask for the final FDA rule when someone claims that a meeting opened access.
Brief source notes
- FDA’s record of epitalon’s rare-disease status
The record shows support for work on a rare disease, not approval to use the medicine.
- FDA’s list of requests taken back
FDA still lists its safety concerns after the requests to use epitalon were taken back.
- FDA’s public meeting page
This is the place to look for an official meeting record.
- The compounding ingredient rule
The regulation sets out the permitted ingredient list.